- Home
- VMD vs FHTX Comparison
VMD vs FHTX Comparison
Compare VMD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- FHTX
- Stock Information
- Founded
- VMD 2006
- FHTX 2015
- Country
- VMD United States
- FHTX United States
- Employees
- VMD N/A
- FHTX N/A
- Industry
- VMD
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- VMD
- FHTX Health Care
- Exchange
- VMD Nasdaq
- FHTX Nasdaq
- Market Cap
- VMD 273.5M
- FHTX 271.5M
- IPO Year
- VMD N/A
- FHTX 2020
- Fundamental
- Price
- VMD $6.74
- FHTX $5.40
- Analyst Decision
- VMD
- FHTX Strong Buy
- Analyst Count
- VMD 0
- FHTX 8
- Target Price
- VMD N/A
- FHTX $12.63
- AVG Volume (30 Days)
- VMD 198.2K
- FHTX 144.3K
- Earning Date
- VMD 08-06-2025
- FHTX 08-07-2025
- Dividend Yield
- VMD N/A
- FHTX N/A
- EPS Growth
- VMD 19.95
- FHTX N/A
- EPS
- VMD 0.30
- FHTX N/A
- Revenue
- VMD $232,793,000.00
- FHTX $23,504,000.00
- Revenue This Year
- VMD $17.35
- FHTX $44.01
- Revenue Next Year
- VMD $12.87
- FHTX $9.45
- P/E Ratio
- VMD $22.90
- FHTX N/A
- Revenue Growth
- VMD 19.97
- FHTX N/A
- 52 Week Low
- VMD $6.14
- FHTX $2.95
- 52 Week High
- VMD $9.81
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- VMD 45.43
- FHTX 64.55
- Support Level
- VMD $6.86
- FHTX $4.78
- Resistance Level
- VMD $7.07
- FHTX $5.52
- Average True Range (ATR)
- VMD 0.22
- FHTX 0.32
- MACD
- VMD -0.01
- FHTX 0.05
- Stochastic Oscillator
- VMD 27.14
- FHTX 86.67
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.